Guangdong VTR Bio-Tech Co Ltd
Guangdong VTR Bio-Tech Co., Ltd. researches, develops, produces, sells, and services bio-enzyme preparations, biosynthetics, and nutrition and health products in China and internationally. The company offers animal nutrition and health, biofuel, detergent, food and beverage, brewing, starch sweetness, bakery, plant extracts, pulp and paper, and textile enzymes, as well as biotechnology solutions.… Read more
Guangdong VTR Bio-Tech Co Ltd (300381) - Net Assets
Latest net assets as of September 2025: CN¥2.64 Billion CNY
Based on the latest financial reports, Guangdong VTR Bio-Tech Co Ltd (300381) has net assets worth CN¥2.64 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.89 Billion) and total liabilities (CN¥258.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.64 Billion |
| % of Total Assets | 91.05% |
| Annual Growth Rate | 23.08% |
| 5-Year Change | -18.66% |
| 10-Year Change | 87.5% |
| Growth Volatility | 35.44 |
Guangdong VTR Bio-Tech Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how Guangdong VTR Bio-Tech Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guangdong VTR Bio-Tech Co Ltd (2007–2024)
The table below shows the annual net assets of Guangdong VTR Bio-Tech Co Ltd from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.65 Billion | -2.96% |
| 2023-12-31 | CN¥2.74 Billion | -2.87% |
| 2022-12-31 | CN¥2.82 Billion | -7.62% |
| 2021-12-31 | CN¥3.05 Billion | -6.59% |
| 2020-12-31 | CN¥3.26 Billion | +19.58% |
| 2019-12-31 | CN¥2.73 Billion | +13.38% |
| 2018-12-31 | CN¥2.41 Billion | +15.14% |
| 2017-12-31 | CN¥2.09 Billion | +1.73% |
| 2016-12-31 | CN¥2.05 Billion | +45.14% |
| 2015-12-31 | CN¥1.42 Billion | +106.54% |
| 2014-12-31 | CN¥685.38 Million | +124.16% |
| 2013-12-31 | CN¥305.76 Million | +25.97% |
| 2012-12-31 | CN¥242.72 Million | +29.11% |
| 2011-12-31 | CN¥188.00 Million | +29.83% |
| 2010-12-31 | CN¥144.81 Million | +16.98% |
| 2009-12-31 | CN¥123.79 Million | +26.17% |
| 2008-12-31 | CN¥98.12 Million | +26.19% |
| 2007-12-31 | CN¥77.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong VTR Bio-Tech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1282.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥502.30 Million | 19.23% |
| Common Stock | CN¥491.06 Million | 18.80% |
| Other Comprehensive Income | CN¥104.44 Million | 4.00% |
| Other Components | CN¥1.51 Billion | 57.96% |
| Total Equity | CN¥2.61 Billion | 100.00% |
Guangdong VTR Bio-Tech Co Ltd Competitors by Market Cap
The table below lists competitors of Guangdong VTR Bio-Tech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dongjiang Environmental Company Limited
PINK:SZDEF
|
$313.62 Million |
|
CIR S.p.A. - Compagnie Industriali Riunite
F:BN7
|
$313.63 Million |
|
Yuanta Futures Co Ltd
TWO:6023
|
$313.67 Million |
|
Infibeam Avenues Limited
NSE:INFIBEAM
|
$313.70 Million |
|
Dalian Haosen Equipment Manufacturing Co. Ltd. A
SHG:688529
|
$313.44 Million |
|
Shenzhen Longood Intelligent Electric Co Ltd Class A
SHE:300543
|
$313.23 Million |
|
Theravance Biopharma Inc
NASDAQ:TBPH
|
$313.22 Million |
|
Peugeot Invest SA
PA:PEUG
|
$313.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong VTR Bio-Tech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,614,531,882 to 2,611,511,969, a change of -3,019,913 (-0.1%).
- Net income of 31,091,854 contributed positively to equity growth.
- Dividend payments of 34,553,301 reduced retained earnings.
- Other comprehensive income decreased equity by 10,875,818.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥31.09 Million | +1.19% |
| Dividends Paid | CN¥34.55 Million | -1.32% |
| Other Comprehensive Income | CN¥-10.88 Million | -0.42% |
| Other Changes | CN¥11.32 Million | +0.43% |
| Total Change | CN¥- | -0.12% |
Book Value vs Market Value Analysis
This analysis compares Guangdong VTR Bio-Tech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.34x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 22.86x to 1.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.32 | CN¥7.27 | x |
| 2008-12-31 | CN¥0.40 | CN¥7.27 | x |
| 2009-12-31 | CN¥0.51 | CN¥7.27 | x |
| 2010-12-31 | CN¥0.62 | CN¥7.27 | x |
| 2011-12-31 | CN¥0.80 | CN¥7.27 | x |
| 2012-12-31 | CN¥1.03 | CN¥7.27 | x |
| 2013-12-31 | CN¥1.31 | CN¥7.27 | x |
| 2014-12-31 | CN¥2.44 | CN¥7.27 | x |
| 2015-12-31 | CN¥4.22 | CN¥7.27 | x |
| 2016-12-31 | CN¥4.95 | CN¥7.27 | x |
| 2017-12-31 | CN¥4.77 | CN¥7.27 | x |
| 2018-12-31 | CN¥5.27 | CN¥7.27 | x |
| 2019-12-31 | CN¥5.60 | CN¥7.27 | x |
| 2020-12-31 | CN¥6.08 | CN¥7.27 | x |
| 2021-12-31 | CN¥5.70 | CN¥7.27 | x |
| 2022-12-31 | CN¥5.59 | CN¥7.27 | x |
| 2023-12-31 | CN¥5.33 | CN¥7.27 | x |
| 2024-12-31 | CN¥5.44 | CN¥7.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong VTR Bio-Tech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.76%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.13x
- Recent ROE (1.19%) is below the historical average (9.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 15.46% | 13.43% | 0.69x | 1.67x | CN¥4.06 Million |
| 2008 | 20.77% | 13.25% | 0.86x | 1.82x | CN¥10.12 Million |
| 2009 | 20.53% | 13.61% | 0.92x | 1.63x | CN¥12.56 Million |
| 2010 | 19.55% | 13.00% | 0.95x | 1.59x | CN¥13.77 Million |
| 2011 | 23.05% | 15.96% | 1.04x | 1.38x | CN¥24.44 Million |
| 2012 | 22.61% | 16.22% | 1.14x | 1.22x | CN¥30.51 Million |
| 2013 | 20.69% | 17.58% | 0.95x | 1.23x | CN¥32.62 Million |
| 2014 | 8.31% | 15.32% | 0.37x | 1.45x | CN¥-11.19 Million |
| 2015 | 5.54% | 10.21% | 0.29x | 1.89x | CN¥-57.76 Million |
| 2016 | 5.98% | 7.51% | 0.47x | 1.69x | CN¥-76.39 Million |
| 2017 | 4.15% | 5.36% | 0.39x | 1.98x | CN¥-113.44 Million |
| 2018 | 5.30% | 6.42% | 0.37x | 2.24x | CN¥-100.69 Million |
| 2019 | 5.17% | 6.23% | 0.45x | 1.83x | CN¥-119.00 Million |
| 2020 | 5.43% | 8.45% | 0.41x | 1.57x | CN¥-136.10 Million |
| 2021 | -4.26% | -6.28% | 0.42x | 1.60x | CN¥-398.19 Million |
| 2022 | 0.67% | 1.55% | 0.37x | 1.17x | CN¥-252.36 Million |
| 2023 | -0.41% | -1.35% | 0.26x | 1.18x | CN¥-272.20 Million |
| 2024 | 1.19% | 3.76% | 0.28x | 1.13x | CN¥-230.06 Million |
Industry Comparison
This section compares Guangdong VTR Bio-Tech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,249,192,405
- Average return on equity (ROE) among peers: 10.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong VTR Bio-Tech Co Ltd (300381) | CN¥2.64 Billion | 15.46% | 0.10x | $313.62 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.28 Million | -13.04% | 0.97x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $687.82 Million | 11.47% | 1.00x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $134.48 Million | 10.88% | 3.14x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $915.76 Million | -0.65% | 0.06x | $253.71 Million |
| Chengzhi Shareholding Co Ltd (000990) | $997.75 Million | 5.11% | 1.23x | $934.96 Million |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $1.99 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $7.66 Billion | 47.23% | 0.35x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $31.94 Billion | 6.87% | 0.05x | $3.75 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $403.60 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.14 Billion | 14.05% | 0.13x | $344.80 Million |